AstraZeneca
AstraZeneca bills itself as a science-led biopharmaceutical business. The British-Swiss company develops and manufactures products for a variety of conditions, including cancer, Type 2 diabetes, and respiratory issues. AstraZeneca’s top product by revenue has been Tagrisso, a medication used to treat non-small-cell lung carcinomas.
Latest
STAT Plus: As Medicare drug pricing negotiations begin, AstraZeneca stays mum on government’s offer
STAT Plus: Data on AstraZeneca cancer drug allay safety concerns but treatment still faces questions
STAT Plus: In lung cancer, J&J data amount to latest salvo against AstraZeneca
STAT Plus: AstraZeneca CEO Pascal Soriot proposes a novel fix to the drug pricing law’s alleged cancer problem
STAT Plus: AstraZeneca bets that gene therapy’s workhorse will still deliver the goods
STAT Plus: AstraZeneca sues to stop Medicare drug price negotiation program
Get ready for more drug ads: Facebook is making a bid for pharma dollars
All Coverage
advertisement
